Sun Pharma Q1 Results FY27: PAT at Rs 2,910 Cr for June 2026 Quarter

The Sun Pharma Q1 results FY27 show consolidated revenue of Rs 15,299 Cr for the quarter ended 30 June 2026, +10.46% from Rs 13,851 Cr in Q1 FY26, as Sun Pharma reported its numbers on 31 July 2026.

Sun Pharma posted a net profit (PAT) of Rs 2,910 Cr for the quarter, against Rs 2,302 Cr a year earlier. Shares traded around Rs 1,987 on the NSE, down 0.18% on the day, as investors weighed the print against trends in the pharmaceuticals sector. Here is a full breakdown of the financial highlights, key business factors, dividend status, outlook and risks.

Click Here – Get Free Investment Predictions

Sun Pharma Q1 Results FY27 Financial Highlights

The table below summarises Sun Pharma's consolidated numbers for the quarter against the year ago period.

Metric	Q1 FY27 (Jun 2026)	Q1 FY26 (Jun 2025)	YoY Change
Revenue	Rs 15,299 Cr	Rs 13,851 Cr	+10.46%
Gross Profit	Rs 3,678 Cr	Rs 3,601 Cr	+2.16%
Gross Profit Margin	24.0%	26.0%	-2.0 pts
Net Profit (PAT)	Rs 2,910 Cr	Rs 2,302 Cr	+26.41%
Net Profit Margin	19.0%	16.6%	+2.4 pts

Sun Pharma Q1 FY27 Performance Analysis

Revenue growth was the standout number for the quarter. Sales rose +10.46% year on year to Rs 15,299 Cr, up from Rs 13,851 Cr in the year ago period, as demand held firm through the June quarter.

Cost pressures show up clearly in the release, with gross profit changing +2.16% year on year to Rs 3,678 Cr (24.0% margin) even as the topline moved differently, pointing to margin compression during the period.

The bottom line followed through on the operating performance. Net profit increased +26.41% year on year to Rs 2,910 Cr, up from Rs 2,302 Cr in Q1 FY26, translating the quarter's operating trends into a stronger PAT print.

Check the Univest Screener for Live Data

Sun Pharma Q1 FY27: Key Business Factors

1. Revenue Growth Trajectory

Sun Pharma reported revenue of Rs 15,299 Cr for the June 2026 quarter against Rs 13,851 Cr in the year ago period, a change of +10.46%. This pace of change is a primary swing factor behind the quarter's numbers, and investors typically track whether it holds up in the following quarters.

2. Gross Margin and Cost Trends

Gross profit moved from Rs 3,601 Cr in Q1 FY26 to Rs 3,678 Cr in Q1 FY27, a change of +2.16%. In the pharmaceuticals sector, this line is sensitive to raw material and API cost volatility, regulatory approvals and pricing pressure in key markets, and this quarter's numbers reflect how Sun Pharma managed that balance.

3. Bottom Line and Earnings Quality

Net profit moved from Rs 2,302 Cr in Q1 FY26 to Rs 2,910 Cr this quarter, up +26.41%. On a reported basis this is the figure that flows through to earnings per share, and it is usually the first number investors check.

Dividend Details

Specific dividend information was not confirmed as part of this results snapshot. Investors should check the official exchange filing on the NSE or BSE website, or track the Univest Screener, for the latest dividend announcement, record date and payment date from Sun Pharma.

Sun Pharma Outlook for FY27

This quarter sets the tone for the rest of FY27. If the growth in revenue and improvement in net profit persist, analysts are likely to revisit their FY27 estimates for Sun Pharma. Investors should also watch input costs and demand trends in the pharmaceuticals sector through the year.

Sun Pharma Stock Performance After the Results

Sun Pharma shares traded around Rs 1,987 on the NSE, down 0.18% around the time the results were in focus. The 52 week trading range was not confirmed as part of this snapshot; investors can check the live 52 week high and low, along with technical levels, on the Univest Screener before making any trading decision.

Download the Univest iOS App or Univest Android App to track Sun Pharma live share price and upcoming quarterly results.

Key Risks

Investors reading through Sun Pharma's numbers should also weigh the following risks.

1. Margin and Input Cost Risk

Being in the pharmaceuticals sector, Sun Pharma remains exposed to raw material and API cost volatility, regulatory approvals and pricing pressure in key markets. A reversal in the trend seen this quarter could pressure margins in coming quarters.

2. Execution and Working Capital Risk

Execution risk around working capital, receivables and order timelines can cause quarter to quarter volatility in reported numbers, so this quarter's trends should be read over a few quarters rather than in isolation.

3. Macro and Sector Risk

Broader macro factors including interest rates, currency movements and demand cycles in the pharmaceuticals sector could influence how sustainable this quarter's trends prove to be over FY27.

Conclusion

The Sun Pharma Q1 results FY27 show revenue of Rs 15,299 Cr and Rs 2,910 Cr for the quarter, against Rs 13,851 Cr and Rs 2,302 Cr in Q1 FY26. Revenue growth and a stronger bottom line were the two moving parts this quarter. Investors tracking Sun Pharma should watch the next few quarters for confirmation of this trend and consult a SEBI-registered advisor before making investment decisions based on these numbers.

Frequently Asked Questions on Sun Pharma Q1 Results FY27

When were the Sun Pharma Q1 results FY27 announced?

Ans. They reflect the quarter ended 30 June 2026, with the data reported as of 31 July 2026. Investors should confirm the exact board meeting date from the official NSE or BSE filing.

What is the PAT in Sun Pharma's Q1 FY27 results?

Ans. The PAT stood at Rs 2,910 Cr, compared with Rs 2,302 Cr in Q1 FY26, a change of +26.41%.

What was the revenue in Sun Pharma's Q1 FY27 results?

Ans. Revenue came in at Rs 15,299 Cr for the quarter, a change of +10.46%, compared with Rs 13,851 Cr in Q1 FY26.

Did Sun Pharma declare a dividend with the Q1 FY27 results?

Ans. Dividend details were not confirmed as part of this results snapshot. Check the latest exchange filing on NSE or BSE, or the Univest Screener, for confirmation.

What is the outlook for Sun Pharma after Q1 FY27?

Ans. Analysts will track whether the growth in revenue and improvement in profit continue into the September 2026 quarter, along with input cost and demand trends in the pharmaceuticals sector.

How did the stock react to Sun Pharma's Q1 FY27 results?

Ans. Shares traded around Rs 1,987 on the NSE, down 0.18% as the numbers came into focus.

Is Sun Pharma a good buy after the Q1 FY27 results?

Ans. The quarter shows a net profit of Rs 2,910 Cr on revenue of Rs 15,299 Cr. This article is for educational purposes only and is not investment advice. Consult a SEBI-registered advisor before making any investment decision.